AGTC Awaits Gene Therapy Data, FDA Delays Decision On Elagolix, KPTI On Watch – Nasdaq
Nasdaq |
AGTC Awaits Gene Therapy Data, FDA Delays Decision On Elagolix, KPTI On Watch
Nasdaq Applied Genetic Technologies Corp. (AGTC) has completed enrollment in its phase I/II study of its gene therapy product candidate for the treatment of x-linked retinoschisis (XLRS). XLRP is an inherited condition that causes boys to develop night … |
